CRISPR-Cas9 delivery via LNP: mechanism and design
mRNA-based LNP delivery of CRISPR components offers transient expression, no genomic integration risk, and a dose-titratable safety profile that viral vectors cannot match.
From injection to nuclear editing
IV Administration & ApoE Opsonization
LNP is administered intravenously. In circulation, ApoE adsorbs to the PEG-lipid corona, acting as a ligand for LDLR-mediated endocytosis in hepatocytes. This ApoE-mediated mechanism is the primary driver of hepatic selectivity.
Receptor-Mediated Uptake
LDLR on hepatocyte surface binds ApoE-coated LNP → clathrin-mediated endocytosis. Particle enters early endosome (pH ~6.5) then late endosome (pH ~5.0).
Endosomal Escape
Ionizable lipid protonates at pH 5.0. Positively charged ionizable lipid interacts with negatively charged phospholipids in the endosomal membrane → hexagonal phase transition → membrane destabilization → mRNA released into cytoplasm.
Translation & Editing
Released Cas9 mRNA is translated by ribosomes. Cas9 protein assembles with co-delivered guide RNA → ribonucleoprotein complex enters nucleus → target DNA cut at the guide RNA-specified locus. Expression is transient (Cas9 mRNA half-life ~8 hours in hepatocytes).
LNP vs. AAV for in-vivo CRISPR
| Property | LNP (Gendelivr) | AAV | Lentivirus |
|---|---|---|---|
| Genomic integration risk | None (mRNA, transient) | Low (<1%) | High (by design) |
| Payload capacity | Unlimited | ~4.7 kb (limiting for base editors) | ~8 kb |
| Re-dosing | Possible (no pre-existing immunity) | Limited (anti-AAV antibodies) | Not applicable |
| Manufacturing | GMP microfluidic (scalable) | Baculovirus or HEK293 (complex) | HEK293 transfection (complex) |
| Regulatory precedent | mRNA COVID vaccines, siRNA | Approved products (Luxturna, Zolgensma) | Approved (CAR-T products) |
Optimizing CRISPR LNP delivery for your program
Tell us your Cas9 mRNA length, sgRNA design, and target tissue — Gendelivr's Formulation Engine will run the screen optimized for those parameters.